Table 1 Baseline characteristics of HIV-infected children alive at 24 months after early antiretroviral treatment initiation (ANRS-Pediacam Study, 2008–2013, Cameroon) (N = 149)
N | % (n) or median (IQR) | |
|---|---|---|
Male | 149 | 55.0 (82) |
Site of ART delivery | 149 | |
CME/FCB | 51.7 (77) | |
HLD | 22.2 (33) | |
CHE | 26.1 (39) | |
At 24 months after ART initiation (Study start) | ||
Age at 2 years after ART initiation | 149 | |
< 28 months (treatment initiated before age 4 months of age) | 50.3 (75) | |
[28–30[months (treatment initiated between age 4 and 6 months) | 30.2 (45) | |
≥ 30 months (treatment initiated from 6 months of age) | 19.5 (29) | |
Median in months (IQR) | 28.5 (27.1–30.0) | |
Time period | 149 | |
2010–2011 | 65.1 (97) | |
2012–2013 | 34.9 (52) | |
ART regimen | 149 | |
Lopinavir-based | 74.5 (111) | |
Nevirapine-based | 25.5 (38) | |
Children living with | 131 | |
Both parents | 38.9 (51) | |
Mother only | 36.7 (48) | |
Father only | 5.3 (7) | |
Other relatives | 19.1 (25) | |
Family size ≤ 5 people | 94 | 47.9 (45) |
Access at child’s home to | 94 | |
Refrigerator | 51.1 (48) | |
Running water | 39.4 (37) | |
Electricity | 93.6 (88) | |
CD4 percentage at 2 years after ART initiation | 131 | |
< 15 | 6.1 (8) | |
[15–20[ | 6.1 (8) | |
20–25[ | 14.5 (19) | |
≥ 25 | 73.3 (96) | |
Not measured | 13 | |
Median (IQR), N = 131 | 33.6 (24.5–41.6) | |
Virological status | ||
Achievement of confirmed virological success (CVS) within the first two years of ART | 149 | |
Yes (=2 VL < 1000 copies/mL for two consecutive measurements) | 77.2 (115) | |
No | 22.8 (34) | |
Virological status at 2 years (±3 months) after ART initiation | 134 | |
VL < 400 copies/mL | 67.2 (90) | |
VL ≥ 400 copies/mL | 32.8 (44) | |
VL not measured | 15 | |
Last viral load if not available at 2 years ± 3 months after ART initiation | 15 | |
VL < 400 copies/mL | 12 | |
VL ≥ 400 copies/mL | 3 | |